The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Phase I/II study of decitabine, venetoclax, and ivosidenib or enasidenib in IDH-mutated AML
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promising results of a Phase I/II study (NCT04774393) evaluating the safety and efficacy of an all-oral triplet regimen combining decitabine, venetoclax, and either ivosidenib or enasidenib in patients with IDH1- or IDH2-mutated acute myeloid leukemia (AML). In the newly diagnosed cohort, the regimen achieved a composite complete remission rate of 86% in the ivosidenib arm and 91% in the enasidenib arm, with low early mortality. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
